[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]
Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors.
Bramble MS1,2, Hoff N1, Gilchuk P3, Mukadi P4, Lu K5, Doshi RH1, Steffen I5, Nicholson BP6, Lipson A1, Vashist N2, Sinai C1, Spencer D1, Olinger G7, Wemakoy EO8, Illunga BK9, Pettitt J10, Logue J10, Marchand J10, Varughese J10, Bennett RS10, Jahrling P10, Cavet G11, Serafini T11, Ollmann Saphire E12,13, Vilain E2, Muyembe-Tamfum JJ4, Hensely LE10,14, Simmons G5, Crowe JE Jr3,15, Rimoin AW1.
Author information: 1 Department of Epidemiology, School of Public Health, University of California, Los Angeles. 2 Department of Genetic Medicine Research, Children’s Research Institute, Children’s National Medical Center, Washington, District of Columbia. 3 Vanderbilt Vaccine Center, and Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee. 4 Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo. 5 Blood Systems Research Institute, and Department of Laboratory Medicine, University of California, San Francisco. 6 Institute for Medical Research, Durham Veterans Affairs Medical Center, North Carolina. 7 Boston University, School of Medicine, Department of Medicine, Massachusetts. 8 Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo. 9 Direction de la Lutte Contre les Maladies, Ministère de la Sante, Kinshasa, Democratic Republic of the Congo. 10 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Frederick, Maryland. 11 Atreca, Inc, Redwood City. 12 Skaggs Institute for Chemical Biology, La Jolla, California. 13 Department of Immunology and Microbial Science, Scripps Research Institute, La Jolla, California. 14 Emerging Viral Pathogens Section, NIAID, NIH, Frederick, Maryland. 15 Departments of Pediatrics and Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
One year after a Zaire ebolavirus (EBOV) outbreak occurred in the Boende Health Zone of the Democratic Republic of the Congo during 2014, we sought to determine the breadth of immune response against diverse filoviruses including EBOV, Bundibugyo (BDBV), Sudan (SUDV), and Marburg (MARV) viruses. After assessing the 15 survivors, 5 individuals demonstrated some degree of reactivity to multiple ebolavirus species and, in some instances, Marburg virus. All 5 of these survivors had immunoreactivity to EBOV glycoprotein (GP) and EBOV VP40, and 4 had reactivity to EBOV nucleoprotein (NP). Three of these survivors showed serologic responses to the 3 species of ebolavirus GPs tested (EBOV, BDBV, SUDV). All 5 samples also exhibited ability to neutralize EBOV using live virus, in a plaque reduction neutralization test. Remarkably, 3 of these EBOV survivors had plasma antibody responses to MARV GP. In pseudovirus neutralization assays, serum antibodies from a subset of these survivors also neutralized EBOV, BDBV, SUDV, and Taï Forest virus as well as MARV. Collectively, these findings suggest that some survivors of naturally acquired ebolavirus infection mount not only a pan-ebolavirus response, but also in less frequent cases, a pan-filovirus neutralizing response.
PMID: 30107445 PMCID: PMC6217721 DOI: 10.1093/infdis/jiy453 [Indexed for MEDLINE] Free PMC Article
Keywords: Ebola; Filovirus; Marburg; Serology.